Kidney Fibrosis Pipeline Therapeutics Development Review H2 2015

Press Release   •   Jan 13, 2016 09:28 EST

Kidney Fibrosis - Pipeline Review, H2 2015

Kidney Fibrosis - Pipeline Review, H2 2015 market research report is the latest addition to and its collection of therapeutics business intelligence reports aimed to help take better decisions.

This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Kidney Fibrosis” addition with 33 market data tables and 14 figures, spread across 121 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

AbbVie Inc., Angion Biomedica Corp., Bio-inRen, BioLineRx, Ltd., BiOrion Technologies B.V., Cellmid Limited, Evotec AG, Galectin Therapeutics, Inc., GenKyoTex S.A., GNI Group Ltd., Intercept Pharmaceuticals, Inc., Isarna Therapeutics GmbH, Lpath, Inc., MorphoSys AG, ProMetic Life Sciences Inc., Raptor Pharmaceuticals Corp., Regulus Therapeutics Inc. and SciFluor Life Sciences, LLC

Drugs Profile Discussed in this Research:

ANG-3070, ANG-3586, ANG-4011, ANG-4021, BOT-191, BRN-1889, CAB-101, CGEN-856, CT-140, cysteamine DR, Drug to Inhibit Galectin-3 for Fibrosis, Drugs for Tissue Fibrosis, F-351, Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis, GKT-136901, GRMD-02, ICG-001, INT-767, ISTH-0047, LJ-1888, Lpathomab, MOR-107, P-007, PBI-4050, PBI-4419, Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome, SAR-339375, Small Molecules for Fibrosis, Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis, Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases, SOL-1 and Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Renal Therapeutics Market.

The global kidney and renal diseases market represented steady growth for its four indications, chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury. The forecast represents high growth in diagnosis rates, strong pipeline products and safety, efficacy and more survival rates while the treatment is ongoing.

The renal disease therapeutics market supports with the increase in the number of kidney transplantation, improvement in drug treatments and building stronger patient confidence in the procedure. Also, the options are available to treat the diseases by using novel drugs with other new technology, such as stem cell therapy and immunoglobulin therapy. The kidney organ transplantation market reduced globally due to the generic erosion of immuno suppressant drugs used for kidney transplantation maintenance. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries